Evidence map›Paper›PMID 31837974›Full record

ArticleThe Lancet. Public health2020

Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study.

Aline Dugravot, Aurore Fayosse, Julien Dumurgier, Kim Bouillon, Tesnim Ben Rayana, Alexis Schnitzler, Mika Kivimaki, Séverine Sabia, Archana Singh-Manoux

Abstract read
In one paragraph

Article in The Lancet. Public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Addressing Power in Local-Level Policies and Programs to Reduce Health Inequities - A Systematic Review.International journal of social determinants of health and health services · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Residual diabetic foot osteomyelitis after surgery leads to poor clinical outcomes: A systematic review and meta-analysis.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Aline DugravotInserm U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Paris, France.
Aurore FayosseInserm U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Paris, France.
Julien DumurgierInserm U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Paris, France; Cognitive Neurology Center, Hôpitaux Universitaires Saint-Louis, Lariboisière, Fernand-Widal, Assistance Hôpitaux Publique de Paris, Université de Paris, Paris, France.
Kim BouillonDépartement d'Information Médicale, Centre Hospitalier de Saint-Brieuc, Saint-Brieuc, France.
Tesnim Ben RayanaInserm U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Paris, France.
Alexis SchnitzlerInserm U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Paris, France.
Mika KivimakiDepartment of Epidemiology and Public Health, University College London, London, UK.
Séverine SabiaInserm U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Paris, France; Department of Epidemiology and Public Health, University College London, London, UK.
Archana Singh-ManouxInserm U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Paris, France; Department of Epidemiology and Public Health, University College London, London, UK. Electronic address: archana.singh-manoux@inserm.fr.

Funding

Education, socioeconomic status and Aging: transitions from multimorbidity to functional limitations and mortalityR01AG056477 · NIA · UNIVERSITY COLLEGE LONDON · PI KIVIMAKI, MIKA J, SINGH-MANOUX, ARCHANA · 2018 to 2022
$2.8M
Role of mid- and late-life risk factors in social inequalities in Alzheimer's Disease and Related DementiasRF1AG062553 · NIA · INSERM PARIS 5 · PI KIVIMAKI, MIKA J, SINGH-MANOUX, ARCHANA · 2019 to 2019
$1.5M
British Heart Foundation RG/16/11/32334Medical Research Council MR/R024227/1Medical Research Council MR/S011676/1NIA NIH HHS R01 AG056477NIA NIH HHS RF1 AG062553
6 · The paper itself

Abstract

backgroundSocial inequalities in mortality persist in high-income countries with universal health care, and the mechanisms by which these inequalities are generated remain unclear. We aimed to examine whether social inequalities were present before or after the onset of adverse health conditions (multimorbidity, frailty, and disability).

methodsOur analysis was based on data from the ongoing Whitehall II cohort study, which enrolled British civil servants aged 35-55 years in 1985-88. Participants were assessed for three indicators of socioeconomic status (education, occupational position, and literacy) at age 50 years. Participants underwent clinical examinations (in 2002-04, 2007-09, 2012-13, and 2015-16) for assessment of frailty (two or more of low physical activity, slow walking speed, poor grip strength, weight loss, and exhaustion) and disability (two or more difficulties in bathing, dressing, going to the toilet, transferring, feeding, and walking). In addition, electronic health records were used to assess the incidence of multimorbidity (two or more of diabetes, coronary heart disease, stroke, chronic obstructive pulmonary disease, depression, arthritis, cancer, dementia, and Parkinson's disease) and mortality. In analyses adjusted for sociodemographic factors, we used multistate models to examine social inequalities in transitions from healthy state to adverse health conditions and subsequently to mortality.

findingsOf 10 308 individuals in the Whitehall II study cohort, 6425 had relevant data available at 50 years and to the end of follow-up on Aug 31, 2017, and were included in our analysis. Participants were followed up for a median of 23·6 years (IQR 19·6-28·9). 1694 (26·4%) of 6425 participants developed multimorbidity, 1733 (27·0%) became frail, 692 (10·8%) had a disability, and 611 (9·5%) died. Multimorbidity (hazard ratio [HR] 4·12 [95% CI 3·41-4·98]), frailty (HR 2·38 [95% CI 1·93-2·93]), and disability (HR 1·73 [95% CI 1·34-2·22]) were associated with increased risk of mortality; these associations were not modified by socioeconomic status. In multistate models, occupation was the socioeconomic status indicator that was most strongly associated with inequalities in the transition from healthy state to multimorbidity (HR 1·54 [95% CI 1·37-1·73]), to frailty (HR 2·08 [95% CI 1·85-2·33]), and to disability (HR 1·44 [95% CI 1·18-1·74]). Socioeconomic status indicators did not affect transitions to mortality in those with multimorbidity, frailty, or disability.

interpretationSocioeconomic status affects the risk of multimorbidity, frailty, and disability, but does not affect the risk of mortality after the onset of these adverse health conditions. Therefore, primary prevention is key to reducing social inequalities in mortality. Of the three adverse health conditions, multimorbidity had the strongest association with mortality, making it a central target for improving population health.

fundingUK Medical Research Council; National Institute on Aging, National Institutes of Health; British Heart Foundation.

Indexed as

Health Status DisparitiesAgedFemaleFollow-Up StudiesFrail ElderlyFrailtyHumansMaleMiddle AgedMortalityMultimorbidityPersons with DisabilitiesSocioeconomic FactorsUnited Kingdom

Identifiers

PMID31837974
PMCPMC7098476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.